Tandem Diabetes exec vests 1,010 RSUs at $22.72

TANDEM DIABETES CARE INC (TNDM) executive Jean-Claude Kyrillos reported the vesting of restricted stock units and related share movements.

Rhea-AI Filing Summary

TANDEM DIABETES CARE INC (TNDM) executive Jean-Claude Kyrillos reported the vesting of restricted stock units and related share movements. On 2026-08-15, 1,010 RSUs granted on May 30, 2025 under the 2023 Long-Term Incentive Plan were converted into 1,010 shares of common stock. Of these, 535 shares were withheld by the company at $22.72 per share to satisfy tax withholding requirements, with no shares sold in the market, leaving a net 475 shares issued. Following the RSU vesting event, Kyrillos holds 7,067 RSUs that will continue to vest in eight equal quarterly installments, subject to the plan’s terms.

Insider Trade Summary

1,010 shares exercised/converted

Exercise 3 txns

Insider Kyrillos Jean-Claude

Role EVP & Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit F2, F3, F4	1,010	$0.00	$0.00
Exercise	Common Stock	1,010	$0.00	$0.00
Tax Withholding	Common Stock F1	535	$22.72	$12K

Holdings After Transaction: Restricted Stock Unit — 7,067 contracts (Direct); Common Stock — 30,290 shares (Direct)

Footnotes (4)

1. F1. Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold.
2. F2. Awarded on May 30, 2025 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
3. F3. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
4. F4. One-third of the RSUs granted on May 30, 2025 vested on May 15, 2026, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.

Key Figures

RSUs exercised/converted: 1,010 shares Shares withheld for taxes: 535 shares Withholding price: $22.72 per share +2 more

5 metrics

RSUs exercised/converted 1,010 shares Restricted Stock Units converted into common stock on 2026-08-15

Shares withheld for taxes 535 shares Common stock withheld to satisfy tax withholding upon RSU vesting

Withholding price $22.72 per share Price used for shares withheld for tax liability (code F transaction)

Remaining RSUs 7,067 units RSUs held after the vesting event reported in the derivative transaction

Net shares issued from vesting 475 shares 1,010 RSUs converted minus 535 shares withheld for taxes

Key Terms

Restricted Stock Unit, tax withholding requirements, Long-Term Incentive Plan, contingent right, +1 more

5 terms

Restricted Stock Unit financial

"security_title: "Restricted Stock Unit""

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

tax withholding requirements financial

"Shares withheld by the Issuer to satisfy tax withholding requirements"

Long-Term Incentive Plan financial

"pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan"

A long-term incentive plan is a company program that pays executives or employees with stock, options, or cash tied to multi-year performance goals, where the rewards become theirs only after meeting conditions over time. Think of it as a delayed bonus or retirement-style reward that aligns employees’ interests with shareholders by encouraging them to boost long-term value; investors watch these plans because they affect pay costs, share dilution and management incentives.

contingent right financial

"Each RSU represents a contingent right to receive either one share"

vested financial

"One-third of the RSUs granted on May 30, 2025 vested on May 15, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity transaction did TNDM executive Jean-Claude Kyrillos report?

Jean-Claude Kyrillos reported 1,010 restricted stock units vesting and converting into 1,010 TNDM common shares on 2026-08-15. The transaction reflects routine equity compensation vesting under Tandem Diabetes Care’s 2023 Long-Term Incentive Plan.

How many TNDM shares were withheld for taxes in Kyrillos’s Form 4 filing?

The filing shows 535 TNDM common shares were withheld at $22.72 per share to satisfy tax withholding obligations upon RSU vesting. A footnote clarifies these were withheld shares and that no shares were sold in the market.

Did Jean-Claude Kyrillos sell any TNDM shares in this Form 4?

No shares were sold. The Form 4 states 535 shares were withheld by Tandem Diabetes Care to cover tax withholding requirements for vested RSUs, and explicitly notes that no shares were sold into the market.

How many RSUs does Kyrillos still hold after this TNDM transaction?

After the reported vesting, Kyrillos holds 7,067 restricted stock units. According to the disclosure, one-third vested on May 15, 2026, and the remaining RSUs vest in eight equal quarterly installments, subject to the plan’s conditions.

What plan governs the RSU award reported in TNDM’s Form 4 for Kyrillos?

The RSUs were granted under Tandem Diabetes Care’s 2023 Long-Term Incentive Plan. The filing notes the award date as May 30, 2025 and that each RSU entitles Kyrillos to one share of common stock or cash, at the issuer’s discretion.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 04:29 PM Accepted by SEC EDGAR 08/18/2026 - 04:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kyrillos Jean-Claude

(Last) (First) (Middle)

12400 HIGH BLUFF DRIVE

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TANDEM DIABETES CARE INC [ TNDM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2026		M		1,010	A	$0	30,825	D
Common Stock	08/15/2026		F(1)		535	D	$22.72	30,290	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit(2)	(3)	08/15/2026		M			1,010	(4)	(4)	Common Stock	1,010	$0	7,067	D

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold.

2. Awarded on May 30, 2025 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

3. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

4. One-third of the RSUs granted on May 30, 2025 vested on May 15, 2026, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.

Remarks:

	/s/ Jerilyn Laskie, Attorney-in-Fact for Jean-Claude Kyrillos	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)